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Abstract 
Background:  Statins substantially reduce cardiovascular disease risk and are generally well-
tolerated, but many patients discontinue therapy.  A better understanding of the characteristics of 
current and former statin users may be helpful for formulating strategies to improve long-term 
adherence. 
Objective:  The Understanding Statin Use in America and Gaps in Education (USAGE) survey 
assessed the attitudes, beliefs, practices, and behavior of current and former statin users. 
Methods:  Individuals 18 years who reported current or former statin use were identified within 
a registered consumer panel cohort in the United States and invited to participate in an Internet 
survey. 
Results:  Of the 10,138 respondents, 8918 (88%) were current statin users and 1220 (12%) were 
former users.  Participants (mean age 61 years) were predominantly Caucasian (92%), female 
(61%), middle income (median $44,504/yr), and had health insurance (93%).  Among current 
users, 95% took a statin alone (the majority generic) and 70% had not missed a dose in the past 
month.  Although ~70% reported that their physicians had explained the importance of 
cholesterol levels and danger to their heart, former users were less satisfied with the discussions 
(65% vs. 83%, p<0.05).  Muscle-related side effects were reported by 69% and 25% of former 
and current users, respectively (p<0.05).  The primary reason for discontinuation by former users 
was side effects (62%), and the primary reason for switching by current users was cost (32%). 
Conclusions: This survey provides important insights into behavior and attitudes among current 
and former statin users and the results suggest that more effective dialogue between healthcare 
providers and patients may increase persistence of statin use, particularly when the patient has 
concerns about drug costs and side effects.4 
 
Introduction 
Statins (3-hydroxy 3-methyglutaryl coenzyme A (HMG CoA) reductase inhibitors) are highly 
effective for lowering low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein 
(HDL)-C, and apolipoprotein B levels in plasma.  Extensive clinical trial data support their use 
for primary and secondary prevention of cardiovascular disease events,
1-6 and statins are the 
mainstay in dyslipidemia management guidelines.
7  The year 2012 marks the 25
th anniversary of 
the Food and Drug Administration approval of the first statin, lovastatin, indicated to treat 
elevated cholesterol levels not controlled by diet and lifestyle.
8  National Health and Nutrition 
Examination Survey (NHANES) data from 2005-2008 showed that ~25% of Americans over the 
age of 45 were taking a statin drug,
9 and 77.6% of statin users had achieved their National 
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III treatment targets.
10 
 
Despite the widespread prescription of highly effective lipid-lowering medications, a large 
portion of the United States (U.S.) population has LDL-C levels above the recommended 
goals.
7,11-14  Based on recent NHANES data, it has been estimated that 71 million U.S. adults 
(20 years of age) have LDL-C above NCEP ATP-III goals, but only 34 million (48.1%) 
received lipid-lowering treatment (including non-drug therapy) and 23 million (33.2%) achieved 
NCEP ATP III LDL-C goal.
14  The LDL-C treatment goal achievement success rates for subjects 
at low-, moderate-, and high-risk for coronary heart disease (CHD) in the Lipid Treatment 
Assessment Project 2, conducted between September 2006 and April 2007, were 86%, 74%, and 
67%, respectively.
13  Although these results are better than those reported in prior surveys, e.g., 
57% of CHD and CHD risk equivalent patients reached LDL-C treatment goal in the NCEP 5 
 
Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II study
11 and 23% of high-risk 
individuals in NHANES II,
12 substantial room for improvement remains.
15 
 
Gaps in LDL-C goal achievement have been attributed to a variety of causes including the lack 
of access to affordable and appropriate health care, and lipid-lowering medication non-
adherence, including irregular or interrupted intake and lack of persistence (discontinuation).
14,16-
18  It has been reported that 50% or more of patients discontinue statin medication within one 
year after treatment initiation and that consistency of use decreases over time.
19-21  Although not 
surprising, it is important to note that statin nonadherence has been associated with an increased 
risk of adverse cardiovascular outcomes in observational studies
22 and in randomized trials.
23,24 
 
This manuscript presents results of the Understanding Statin Use in America and Gaps in 
Education (USAGE) Survey.  Extensive data from this Internet-based survey of 10,138 current 
and former statin users, to the authors’ knowledge the largest direct patient survey conducted to 
date, are presented herein in order to describe and compare characteristics of current and former 
statin users. 6 
 
Methods 
Study Design 
The Understanding Statin Use in America and Gaps in Education (USAGE) Survey was 
conducted from September 21, 2011 through October 17, 2011 via an Internet-based, self-
administered questionnaire developed by Kantar Health (New York, NY), with input from the 
study authors representing the National Lipid Association, as well as from Kowa 
Pharmaceuticals America, Inc. (Montgomery, AL), and Eli Lilly and Company (Indianapolis, 
IN).  The survey was administered by Lightspeed Online Research, Inc. (New York, NY), a 
subsidiary of Kantar Health.  The study protocol and questionnaire were Health Insurance 
Portability and Accountability Act compliant and were reviewed and approved by the Essex 
Institutional Review Board (Lebanon, NJ). 
 
Participants and Survey 
Individuals with high cholesterol were identified from the Ailment Panel of Lightspeed Online 
Research (Lightspeed Consumer Panel 2009),
25,26 a partner organization that manages an on-line-
registered consumer panel worldwide, using multisource recruiting methodology.  After fielding 
the survey to ~10% of pre-qualified individuals to determine whether any logistical problems 
existed and to confirm the estimated response rate, all potential respondents were invited via e-
mail to participate in a survey research study.  The survey content was not described in the 
invitation.  Approximately two to four days after the initial e-mail invitation, an additional e-mail 
reminder was sent to those who had not previously responded. 
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Persons who expressed a desire to participate were sent a link to a preliminary screening 
questionnaire to assess whether they met the following inclusion criteria: 18 years of age; self-
reported diagnosis of a high cholesterol level made by a health care provider; self-reported 
current or former use of a statin (alone or in combination with another cholesterol-lowering 
medication); ability to read and write English; and residence in the U.S. at the time of the study.  
Respondents who did not meet these inclusion criteria were exited from the survey instrument.  
Those who were eligible were asked to provide informed consent, at which time the topic of the 
survey was explained and resources to address any questions or concerns were provided.  
Individuals who gave their informed consent completed the on-line survey of 89 questions 
related to demographics, employment, disease severity and history, treatment history and 
satisfaction, adherence, attitudes towards statin treatment, sources of information, and health 
resource costs.  The respondents received a small incentive for their participation in the form of 
points that could redeemed for gift certificates with a cash equivalence of less than $1. 
 
Data Analyses 
Chi-square tests and Student’s t-tests were used to identify significant differences between 
current and former statin users with two-sided p-values < 0.05 considered statistically significant.  
Current statin users were defined as those individuals who at the time of the survey responded 
that they were taking a statin (either on its own or in fixed-dose combination with niacin, 
amlodipine, or ezetimibe).  Former statin users were defined as those individuals who indicated 
previous statin use (either on its own or in combination with another medication), but who 
reported not taking a statin at the time of the survey. 8 
 
Results 
Demographic Characteristics 
Of the 27,946 individuals with high cholesterol identified from the Ailment Panel of Lightspeed 
Online Research and contacted by e-mail to participate in the survey, 15,346 (54.9%) responded, 
and of those, 10,138 (n = 8918 current statin users and n = 1220 former statin users) were 
determined to be eligible, provided consent, and completed the survey.  A summary of the 
demographic characteristics of the respondents is shown in Table 1.  Briefly, the majority were 
Caucasian (92%) and more than half were female (61%), with an average age of 61 years.  Most 
of the respondents had at least one co-morbid condition requiring medication(s), such as 
hypertension (66%), diabetes (28%) or CHD (11%).  Additionally, reports of being overweight 
(35%) and obese (46%) were common. 
 
The median 2010 household income among respondents was $44,504, and differed significantly 
between current statin users ($45,270) and former statin users ($39,452, p<0.05).  Overall, 
participants reported spending an average of $88/month on all prescription medications (current 
users, $88 and former users, $84).  The percentage of individuals with any health insurance was 
high in both groups but significantly lower among former statin users (87%) compared with 
current statin users (94%, p<0.05), as was the percentage of individuals with Medicare/Medicaid 
coverage (former users, 43% and current users, 47%; p<0.05).  The percentage of respondents 
who had at least a college degree was similar among current statin users (39%) and former users 
(36%). 
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Statin Use and Lipid Knowledge and Awareness 
The average age at which the diagnosis of high cholesterol was reported to have been made was 
50 years (current users, 50.4 years and former users, 48.8 years; p<0.05).  The reported duration 
between the diagnosis and initiation of statin therapy was about one year on average.  Of current 
statin users, 95% indicated taking a statin alone, i.e. not as a fixed-dose combination.  A small 
fraction (2%) of current users had been prescribed a statin at a dose frequency other than once 
daily.  Among current users, 70% indicated that they had not missed any dose in the past month, 
and only 3% missed six or more doses in the past month.  The majority of survey participants 
indicated that they were currently using, or had previously used, a generic statin (63% of current 
users and 45% of former users, p<0.05), and of those, 21% reported being switched from a 
branded to a generic statin by their pharmacy. 
 
Approximately half of all respondents reported either that were told they had “high” total 
cholesterol (total-C), or were told that their level was 240 mg/dL at the time of their diagnosis.  
Most said that they had their cholesterol checked within the past year, but only 46% recalled 
their most recent level.  Initial (at the time of diagnosis) and current (most recent level) 
respondent-reported levels of total-C and LDL-C are shown in Table 2.  Reported current total-C 
concentrations were significantly lower among current statin users (173.3 mg/dL) compared with 
former statin users (222.7 mg/dL, p<0.05).  Of respondents who recalled their lipid levels both at 
the time of diagnosis and at their most recent appointment, significantly more current statin users 
than former users reported lower current LDL-C compared to that at the time of diagnosis (73% 
vs. 46%, p<0.05). 
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Approximately 25% of study subjects had been told at their last visit that their LDL-C level put 
them at moderately high, high, or very high risk for CHD.  Former statin users were more likely 
to report being told they were at these elevated risk levels than current users (32% vs. 22%, 
p<0.05).  Overall 40% of respondents recalled discussing LDL-C, HDL-C, and triglycerides with 
their physician when they were initially diagnosed, and slightly fewer recalled the discussion at 
their most recent visit (33% of current statin users vs. 29% of former statin users, p<0.05).  Also, 
at their first appointment, approximately two-thirds of respondents (69%) stated that they 
remembered establishing lipid treatment goals with their physician.  Most commonly this was an 
LDL-C treatment goal. 
 
Nearly two-thirds of patients reported being told they should have their cholesterol tested at least 
every six months.  A majority said they adhered to the monitoring recommendations (88% 
current users and 74% former users, p<0.05).  The most commonly cited reasons for less 
frequent monitoring than recommended were inconvenience (27% among former users and 18% 
among current users), cost (21% among former users and 8% among current users), or a belief 
that their cholesterol was under control (16% among former users and 13% among current users) 
(p<0.05 for all comparisons). 
 
Patient-Reported Physician Instruction 
About half of respondents stated that in addition to medication, they were recommended 
therapeutic lifestyle changes (TLC), including diet and exercise when diagnosed (52% of current 
and 48% of former users, p<0.05).  Common physician recommendations included exercise, 
weight loss, low-fat, low-cholesterol diet, and limiting grapefruit consumption.  Significantly 11 
 
more former statin users (60%) than current users (47%) discussed TLC at each visit (p<0.05).  
In contrast, former statin users were less likely than current users to agree that their physicians 
had adequately explained their cholesterol levels (63% vs. 72%, respectively, p<0.05) and how 
high cholesterol levels can affect the heart and arteries (58% vs. 69%, respectively, p<0.05).  
Further, although overall satisfaction with physicians’ explanations of treatments was 81% for all 
participants, former users were less likely than current users to be satisfied (65% vs. 83% 
respectively, p<0.05).  When asked about their typical sources of statin information, half of 
respondents said that their doctor was their only source for statin information (55% current users 
and 41% former users, p<0.05).  Former users relied more heavily on the Internet than current 
users to research statin information (41% vs. 29%, respectively, p<0.05). 
 
Reasons for Switching and Stopping Statins 
Nearly half of all individuals surveyed, 4,637 participants, indicated that they had switched 
statins at least once (Table 3).  Of these, 3,987 (84%) continued to use statins after the switch 
and were current statin users.  The remainder of the respondents (650) either discontinued statin 
therapy sometime after switching, or discontinued without ever having switched from their 
original treatment.  The major reasons for switching or stopping statin use are presented in Table 
3.  Among current users who had switched, 36% cited cost, 28% cited side effects, and 22% 
cited lack of efficacy as the main reason they switched.  Among former users, side effects were 
cited most frequently (65%), while 16% cited cost, and 13% cited lack of efficacy as the reason 
they switched.  Similarly, 62% of former statin users indicated side effects as the reason for 
stopping, compared to 17% who indicated costs and 12% who cited lack of efficacy.  Former 
users also described themselves as less likely to tolerate side effects from prescription 12 
 
medications (54% would stop taking the medication vs. 32% of current users, p<0.05), and more 
willing to make diet and lifestyle changes in order to avoid prescription medication (72% vs. 
57% of current users, p<0.05). 
 
Side Effects and Drug Interactions 
Muscle-related side effects while taking a statin were reported by 29% of all survey participants:  
25% among current users and 60% among former users (p<0.05).  Most respondents discussed 
these side effects with their doctors and it was physicians who most frequently recommended 
stopping or switching statins as the course of action.  However, about one-third of those who 
stopped their statin due to muscle side effects did so without talking to their doctor. 
 
Using the list provided on the survey, 84% of patients indicated that they were taking at least one 
additional medication/supplement which could have the potential to interact with a statin, and, on 
average, respondents reported using three of these medications/supplements.  However, in terms 
of patients’ attitudes toward possible drug-drug interactions, only 38% were concerned about the 
possibility of their medications interacting, 26% proactively talked to their doctor about it, and of 
those who were concerned, 42% believed that their pharmacy would alert them to potential 
interactions.  When queried specifically about eating grapefruit or starfruit while taking a statin, 
47% expressed concern, but most appeared to heed the warning against these fruits, as 82% of all 
respondents reported that they had not consumed either while taking a statin. 13 
 
Discussion 
USAGE is, to the authors’ knowledge, the largest survey of self-reported statin users.  As such, it 
differs from other studies of statin adherence which have analyzed large insurance and pharmacy 
databases.
27  Although valuable, these studies contain only objective data regarding pharmacy 
refills and diagnoses, but lack direct information regarding the patients’ experiences and reasons 
for stopping or switching statin therapy.  Thus, the USAGE survey provides new insights into the 
characteristics of individuals who persist in their use of statins after treatment initiation 
compared to those who have stopped taking statin medication.  Key USAGE findings included 
excellent adherence to daily statin use among most individuals who were currently taking a 
statin, and that the majority of participants felt that their physicians had adequately explained the 
importance of cholesterol elevation and the danger to their heart and arteries.  Also, about half 
had received counseling regarding diet and exercise which is higher than the percentage in the 
Centers for Disease Control National Health Interview Survey in 2010 who reported that they 
had been advised to begin or continue exercise/physical activity by their health care provider 
(32.4%).
28 
 
Overall 81% of USAGE participants were satisfied with their physicians’ care regarding 
cholesterol management.  However, the discrepancy in reported satisfaction with physician 
counseling between those who discontinued their statin (65% satisfied) compared to those who 
continued taking statins (83% satisfied), suggests the need for more intensive patient-physician 
dialogue in order to minimize unnecessary statin discontinuation.  Approximately half of the 
USAGE survey respondents indicated that their physicians were the primary source for 14 
 
information about statin treatment.  Thus, the physician-patient interaction appears to provide the 
greatest opportunity to improve patient education about statin use and improve statin adherence. 
 
Adverse events were cited as the primary reason for discontinuing statins by nearly two-thirds of 
former users.  Previous reports have also noted that side effects, or the perception of side effects, 
can be a major barrier to adherence to treatment with statins.
19,29-30  Interestingly, 25% of the 
individuals currently using statins reported having muscle-related side effects, far more than 
reported by the highly selected subjects in clinical trials.
31,32  Cost was another important reason 
for stopping statin use among former users (17%) and was the primary reason for switching 
among current users (36%).  Results from most other studies of statin adherence and persistence 
have suggested that financial issues are the primary determinants.
19,27,33-37  Higher rates of 
adherence among adults with higher income and a trend toward lower adherence with increasing 
out of pocket costs were shown by Mann et al. in a meta-analysis of 22 cohort studies.
19  The 
average household income and the percentage of USAGE survey respondents with health 
insurance (including Medicare/Medicaid) were somewhat higher among current statin users than 
former statin users. 
 
One-third of the patients who stopped taking a statin due to side effects did so without first 
talking to their doctor.  Kon et al. reported that patients who learned about potential harms of 
statins from non-clinician sources were more likely to be unduly concerned about side effects for 
which they were at low risk.
38  Direct-to-consumer advertising has been reported to provide 
considerable negative information to prospective patients, negatively skewing the perceived risk-
benefit ratio for statin therapy and perhaps impairing statin adherence.
17,38-39  Another major 15 
 
contributor to distortion of the risk-benefit ratio appears to be information obtained from the 
Internet.  In the USAGE survey, former statin users were more likely to have researched statins 
on the Internet than current statin users (41% vs. 29%), although with the data available from the 
USAGE survey, it cannot be inferred whether the Internet searches were cause or effect of 
dissatisfaction with statins. 
 
Statins must be used long-term to provide cardiovascular benefits, and individuals prescribed a 
statin need to understand this, as well as the importance of monitoring LDL-C levels and 
reaching treatment targets.  Of patients who recalled their lipid levels both at the time of 
diagnosis and at their most recent appointment, 73% of current statin users reported 
improvement in LDL-C vs. 46% of former users.  However, only half of all respondents reported 
that lipid treatment goal(s) were established at their initial clinic visit, and about one-quarter 
indicated that they had been told at their last visit that they were still at risk for heart disease 
based on their recent LDL-C level.  The psychological health belief model posits that perceived 
risk of a disease affects behavior.
40  Lower perceived heart disease risk has been shown to be 
associated with lower statin adherence
29 and a greater number of comorbidities, including a 
history of cardiovascular disease or other preexisting conditions, such as hypertension or 
diabetes, has been reported to be associated with increased statin adherence.
19,20,41-45  The 
comorbidity with the highest prevalence in the USAGE survey was hypertension, which was 
reported by 66% of respondents, and significantly more current statins users reported being 
hypertensive compared with former statin users.  Diabetes, a history of coronary 
revascularization (bypass surgery and/or stent); and heart attack or other CHD also were all more 
prevalent among current statin users compared with former statin users.  Based on this 16 
 
information, raising patients’ awareness of the risks associated with elevated LDL-C, and 
providing them with a clear explanation of their treatment target, would be expected to increase 
their adherence to statin treatment. 
 
Among the major limitations of this study is the fact that the respondents were not representative 
of the U.S. population.  USAGE participants were predominantly Caucasian (92%) and these 
results may therefore not apply to other races or ethnicities.  Racial/ethnic minorities are reported 
less likely to be adherent to statins than Caucasian patients.
19,29,42,46  In NEPTUNE II, African 
American patients had a significantly lower frequency of LDL-C treatment success (54%) 
compared with non-Hispanic white individuals (69%) (p<0.001).
47  The USAGE study did not 
include enough minority participants to adequately explore statin use in non-Caucasian groups.  
Furthermore, because the USAGE survey was Internet-based, all participants had Internet access 
and the ability to use this means of communication.  They also had more education than the 
general U.S. population (38% with a college degree vs. 28% in the U.S. population).
48  Further, 
93% of the USAGE participants had health insurance compared with 84% of the general 
population.
49  However, median 2010 household income among respondents was $44,504, which 
is slightly lower than the median household income of roughly $50,000 reported in the 2010 U.S. 
Census.
48  Despite these limitations on generalizability to the general population, USAGE 
subjects were similar to those in other surveys of individuals with access to healthcare, such as 
NEPTUNE II and LTAP 2.
11,13 
 
Self-reporting of medication adherence, such as in the USAGE study, is subject to bias of 
overestimation of a desirable behavior, as well as recall bias.  Interestingly, in the present survey, 17 
 
respondents were more likely to remember their pant size from high school (64%) than their 
most recent cholesterol level (46%).  Despite these obvious limitations, reasonable correlations 
have been found between self-reported diagnoses and physician-reported data for other disorders, 
such as gout, which helps validate the reliability of self-reporting.
50  Another issue which 
potentially limits the generalizability of survey data is selection bias.  Individuals in the database, 
which was used to identify potential participants, are likely different from those not in such a 
database. Also, those who elect to participate in surveys likely differ in many ways from those 
who choose not to participate.  In USAGE, potential respondents were not informed of the topic 
of the survey until they agreed to participate.  This pre-survey single-blind method was used to 
reduce the likelihood of bias due to self-selection for participation in the survey. 
 
Summary and Conclusions 
USAGE is the largest Internet-based survey of attitudes and observations of individuals who 
have taken statins.  Despite the limitations to this survey, primarily the examination of a 
population which was not entirely typical of the general U.S. population, it provides important 
insights into behavior and attitudes among current and former statin users.  Among current users, 
most reported excellent adherence to daily statin use and the majority were taking a generic 
statin, citing cost as a major concern leading to switching statins.  Not surprisingly, current statin 
users reported greater satisfaction with their care than former statin users.  Among former users, 
side effects were cited most often as the reason for stopping, and one-third of former users 
reported that they had stopped their statin without consulting with their healthcare provider.  This 
suggests that more effective dialogue between healthcare providers and patients may help 18 
 
increase adherence and persistence of statin use, particularly when the patient has concerns about 
drug costs and side effects. 
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Table 1.  Demographic characteristics of survey respondents 
Characteristic  Total Respondents 
(n = 10,138) 
Current Statin Users 
(n = 8918) 
Former Statin Users 
(n = 1220) 
  Mean ± SEM 
Age, years  61.0 ± 0.1  61.2 ± 0.1  59.4 ± 0.3* 
Age at Diagnosis  50.2 ± 0.1  50.4 ± 0.1  48.8 ± 0.4 
    Mean %   
Gender       
    Female  61  60  68* 
    Male  39  40  32* 
Race/Ethnicity       
    White  92  92  92 
    Black/African American  4  4  4 
    Asian or Pacific Islander  1  1  1 
    Hispanic  1  1  2 
Current BMI 25 kg/m
2a  81  81  77 
Comorbidity       
    Hypertension  66  67  58* 
    Arthritis  31  31  35* 
    Diabetes  28  29  22* 
    Depression  20  19  22* 
    Gastroesophageal Reflux  19  18  23* 
    Thyroid Condition  17  17  20* 
    Heart Disease
b  11  12  9* 
    Osteopenia  9  8  10* 
    Heart Attack  9  9  7* 
    Osteoporosis  8  7  10* 
aAmong those answering the questions about body mass index, i.e., height and weight (n = 9775; 
n = 8604; n = 1171 for total, current statin user, and former statin user). 
bCoronary heart disease, bypass surgery, and/or a stent 
*Significant different between current and former statin users, p<0.05.29 
 
Table 2.  Initial and current lipid concentrations reported by survey respondents 
Lipid Variable  Total Respondents 
(n = 10,138) 
Current Statin Users 
(n = 8918) 
Former Statin Users  
(n = 1220) 
  Initial  Most recent  Initial  Most recent  Initial  Most recent 
  Mean % With Level 
Total-C
a             
    <150 mg/dL  --  11  --  12  --  3 
    150 to199 mg/dL  --  22  --  23  --  11 
    <200 mg/dL  11  --  11  --  6  -- 
    200 to 239 mg/dL  34  9  34  8  33  17 
    240 to 299 mg/dL  25  3  25  2  29  12 
    300 to 349 mg/dL  8  1  7  0  9  3 
    350 mg/dL  5  0  5  0  6  1 
    Not specific/high  12  --  12  --  12  -- 
    Don’t know  5  54  5  54  5  54 
    Not told  1  --  1  --  1  -- 
LDL-C  (n  = 6386)  (n = 4384)  (n = 5626)  (n = 3856)  (n = 760)  (n = 528) 
    <70 mg/dL  1  12  1  13  1  4* 
    70 to <100 mg/dL  4  17  4  19  3  8* 
    100 to <130  8  11  8  11  8  13 
    130 to <160  12  6  12  5  12  14* 
    Don’t know  71  49  71  49  72  56* 
    Not told  4  4  4  4  5  5 30 
 
aTotal-C concentration categories differed between initial and most recent cholesterol levels. 
*Significantly different between current and former statin users, p<0.05. 
Abbreviations: LDL-C = low-density lipoprotein cholesterol, total-C = total cholesterol 31 
 
Table 3.  Reasons cited for switching or stopping statin medication use among current and 
former statin users who ever switched or stopped taking a statin medication 
  Total 
Respondents 
Current 
Statin Users 
Former 
Statin Users 
   
  Mean % Among Patients Who Ever Switched Statin Medication 
Reason For Switching  (n = 4637)  (n = 3987)  (n = 650) 
Costs (net)  34  36  16* 
Side Effects  33  28  65* 
Efficacy (net)  21  22  13* 
  Mean % Among Former Statin Users  
Reason For Stopping      (n = 1220) 
Costs (net)  NA  NA  17 
Side Effects  NA  NA  62 
Efficacy (net)  NA  NA  12 
*Significantly different between current and former statin users, p<0.05. 
Abbreviation: NA = not applicable 